Terlipressin as rescue therapy for intractable hypotension due to septic shock in children

Shock

Volumn 23, Issue 4, 2005, Pages 305-310

  Matok, Ilan ^a   Vard, Amir ^a,b   Efrati, Ori ^a,b   Rubinshtein, Marina ^a,b   Vishne, Tali ^a,b   Leibovitch, Leah ^a,b   Adam, Miriam ^a   Barzilay, Zohar ^a,b   Paret, Gideon ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Blood pressure; Children; Intractable hypotension; Oxygenation index; Septic shock; Terlipressin; Vasopressin

Indexed keywords

ADRENALIN; CATECHOLAMINE; HYPERTENSIVE FACTOR; INOTROPIC AGENT; TERLIPRESSIN; VASOPRESSIN DERIVATIVE;

ADOLESCENT; ARTERIAL PRESSURE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; HEART RATE VARIABILITY; HEMODYNAMIC MONITORING; HUMAN; HYPOTENSION; INFANT; INTENSIVE CARE UNIT; INTRACTABLE HYPOTENSION; KIDNEY FUNCTION; MALE; NEWBORN; OXYGENATION; PEDIATRICS; PROGNOSIS; RESPIRATORY FUNCTION; RETROSPECTIVE STUDY; REVIEW; SEPTIC SHOCK; SIDE EFFECT; TISSUE PERFUSION; TREATMENT OUTCOME;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CATECHOLAMINES; CHILD; CHILD, PRESCHOOL; CREATININE; EPINEPHRINE; FEMALE; HEART RATE; HUMANS; HYPOTENSION; INFANT; INFANT, NEWBORN; LYSINE VASOPRESSIN; MALE; OXYGEN; PROGNOSIS; SHOCK, SEPTIC; TIME FACTORS;

EID: 16244406253     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000158115.69704.11     Document Type: Review

References (30)

1. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 345:588-595, 2001.
2. Carcillo A, Fields AI: Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 20:1365-1378, 2002.
3. Fink MP, Homer LD, Fletcher JR: Diminished pressor response to exogenous norepinephrine and angiotensin II in septic unanesthetized rats: evidence for a prostaglandin-mediated effect. J Surg Res 38:335-342, 1985.
4. Chernow B, Roth BL: Pharmacologic manipulation of the peripheral vasculature in shock: clinical and experimental approaches. Circ Shock 18:141-155, 1986.
5. Efrati O, Barak A, Ben-Abraham R, Modan-Moses D, Berkovitch M, Manisterski Y, Lotan D, Barzilay Z, Paret G: Should vasopressin replace adrenaline for endotracheal drug administration? Crit Care Med 31:572-576, 2003.
6. Lindner KH, Dirks B, Strohmenger HU, Prengel AW, Lindner IM, Lurie KG: A randomized comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 349:535-537, 1997.
7. Lindner KH, Prengel AW, Brinkmann A, Strohmenger HU, Lindner IM, Lurie KG: Vasopressin administration in refractory cardiac arrest. Ann Intern Med 124:1061-1064, 1996.
8. Prengel AW, Lindner KH, Keller A: Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Stroke 27:1241-1248, 1996.
9. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122-1125, 1997.
10. Loeckinger A, Kleinsasser A, Wenzel V, Mair V, Keller C, Kolbitsch C, Recheis W, Schuster A, Lindner KH: Pulmonary gas exchange after cardiopulmonary resuscitation with either vasopressin or epinephrine. Crit Care Med 30:2059-2062, 2002.
11. Ortiz RM, Cilley RE, Bartlett RH: Extracorporeal membrane oxygenation in pediatric respiratory failure. Pediatr Clin North Am 34:39-46, 1987.
12. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
13. Hatherill M, Waggie Z, Purves L, Reynolds L, Argent A: Mortality and the nature of metabolic acidosis in children with shock. Intensive Care Med 29:286-291, 2003.
14. Ben-Abraham R, Hadad E, Weinbroum AA, Efrati O, Paret G: Vasopressin in cardiac arrest and vasodilatory shock: a forgotten drug for new indication. Isr Med Assoc J 5:272-276, 2003.
15. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA 3rd: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:673-675, 2001.
16. Rosenzweig EB, Stare TJ, Chen JM, Cullinane S, Timchak DM, Gersony WM, Landry DW, Galantowicz ME: Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 100:II182-II186, 1999.
17. Efrati O, Modan-Moses D, Vardi A, Matok I, Bazilay Z, Paret G: Intravenous arginine vasopressin in critically ill children: Is it beneficial? Shock 22:213-217, 2004.
18. Scharte M, Meyer J, Van Aken H, Bone HG: Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 29:1756-1760, 2001.
19. Westphal M, Stubbe H, Sielenkamper AW, Borgulya R, Van Aken H, Ball C, Bone HG: Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 29:301-308, 2003.
20. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. Lancet 359:1209-1210, 2002.
21. Mutlu GM, Factor P: Role of vasopressin in the management of septic shock. Intensive Care Med 30:1276-1291, 2004.
22. Gedeborg R, Silander HC, Ronne-Engstrom E, Rubertsson S, Wiklund L: Adverse effects of high-dose epinephrine on cerebral blood flow during experimental cardiopulmonary resuscitation. Crit Care Med 28:1423-1430, 2000.
23. Gueugniaud PY, Mols P, Goldstein P, Pham E, Dubien PY, Deweerdt C, Vergnion M, Petit P, Carli P: A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group. N Engl J Med 339:1595-1601, 1998.
24. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C: Terlipressin in catecholamine-resistant septic shock patients. Shock 22:314-319, 2004.
25. Matok I, Leibovitch L, Vardi A, Adam M, Rubinshtein M, Barzilay Z, Paret G: Terlipressin as rescue therapy for intractable hypotension during neonatal septic shock. Pediatr Crit Care Med 5:116-118, 2004.
26. Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, Gonzalez-Alonso N, Martinon-Sanchez JM: Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med 30:477-480, 2004.
27. Evora PR, Pearson PJ, Schaff HV: Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. VI-receptor-mediated production of nitric oxide. Chest 103:1241-1245, 1993.
28. Thrush DN, Downs JB, Smith RA: Is epinephrine contraindicated during cardiopulmonary resuscitation? Circulation 96:2709-2714, 1997.
29. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, Lebrec D: Beneficial effects of 2 day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29:565-570, 1998.
30. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK: Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18:152-156, 2003.